Jazz Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Jazz Pharmaceuticals PLC
JAZZ Stock  USD 166.28  0.03  0.02%   
Jazz Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Jazz Pharmaceuticals' valuation are provided below:
Gross Profit
3.8 B
Profit Margin
(0.09)
Market Capitalization
10.1 B
Enterprise Value Revenue
3.2441
Revenue
4.2 B
We have found one hundred twenty available fundamental trends for Jazz Pharmaceuticals PLC, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Jazz Pharmaceuticals PLC regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

Jazz Pharmaceuticals Total Revenue

4.91 Billion

Check Jazz Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jazz Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 287.5 M, Other Operating Expenses of 4 B or Operating Income of 865.3 M, as well as many indicators such as Price To Sales Ratio of 2.04, Dividend Yield of 0.0 or PTB Ratio of 3.99. Jazz financial statements analysis is a perfect complement when working with Jazz Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Jazz Stock
Check out the analysis of Jazz Pharmaceuticals Correlation against competitors.

Jazz Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding52.5 M75.9 M58.5 M
Slightly volatile
Total Assets14.5 B13.8 B6.7 B
Slightly volatile
Short and Long Term Debt Total7.4 B7.1 B3 B
Slightly volatile
Other Current Liabilities1.1 B1 B421.3 M
Slightly volatile
Total Current Liabilities1.3 B1.2 B564.5 M
Slightly volatile
Other Liabilities1.3 B1.2 B580.1 M
Slightly volatile
Property Plant And Equipment Net274.1 M261 M165.7 M
Slightly volatile
Accounts Payable94 M89.5 M47.7 M
Slightly volatile
Cash2.9 B2.8 B978.6 M
Slightly volatile
Non Current Assets Total8.9 B8.5 B4.6 B
Slightly volatile
Non Currrent Assets Other144.5 M137.6 M53 M
Slightly volatile
Other Assets136.8 M197.2 M167 M
Slightly volatile
Cash And Short Term Investments3.6 B3.4 B1.2 B
Slightly volatile
Net Receivables865.5 M824.3 M378.6 M
Slightly volatile
Good Will2.1 B2 B1.1 B
Slightly volatile
Liabilities And Stockholders Equity14.5 B13.8 B6.7 B
Slightly volatile
Non Current Liabilities Total8.3 B7.9 B3.5 B
Slightly volatile
Inventory580.1 M552.5 M259.6 M
Slightly volatile
Other Current Assets530 M504.8 M211.9 M
Slightly volatile
Other Stockholder Equity4.7 B4.5 B2.4 B
Slightly volatile
Total Liabilities9.6 B9.1 B4.1 B
Slightly volatile
Property Plant And Equipment Gross469.7 M447.3 M205.5 M
Slightly volatile
Total Current Assets5.6 B5.3 B2.1 B
Slightly volatile
Intangible Assets5.7 B5.5 B3.1 B
Slightly volatile
Property Plant Equipment363.9 M346.6 M176.7 M
Slightly volatile
Current Deferred Revenue140.2 M133.5 M31.7 M
Slightly volatile
Short Term Debt86.1 M52.6 M84.9 M
Slightly volatile
Common Stock49.4 K70.2 K54 K
Slightly volatile
Common Stock Total Equity5.1 K5.4 K48.6 K
Slightly volatile
Capital Surpluse2.2 B4 B2.2 B
Slightly volatile
Deferred Long Term Liabilities1.1 B1.1 B442.9 M
Slightly volatile
Long Term Debt Total6.9 B6.5 B2.9 B
Slightly volatile
Non Current Liabilities Other107.3 M99.6 M87.5 M
Slightly volatile
Deferred Long Term Asset Charges95.6 M141.3 M108.2 M
Slightly volatile
Short and Long Term Debt33.9 M35.6 M200.2 M
Slightly volatile
Net Invested Capital7.9 B11.7 B6.3 B
Slightly volatile
Long Term Investments4.9 M5.2 M3.6 M
Slightly volatile
Net Working Capital4.3 B4.1 B1.6 B
Slightly volatile
Capital Stock48.8 K54.9 K59.9 K
Slightly volatile
Capital Lease Obligations85.5 M48.3 M132.4 M
Slightly volatile

Jazz Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses4 B3.9 B1.8 B
Slightly volatile
Depreciation And Amortization797 M759.1 M329 M
Slightly volatile
Selling General Administrative1.7 B1.6 B806.1 M
Slightly volatile
Total Revenue4.9 B4.7 B2.2 B
Slightly volatile
Gross Profit4.4 B4.2 B2 B
Slightly volatile
Research Development1.1 B1 B381.4 M
Slightly volatile
Cost Of Revenue538.2 M512.6 M232.1 M
Slightly volatile
Selling And Marketing Expenses31 M29.6 M20.4 M
Slightly volatile
Non Recurring697.7 M664.5 M355.2 M
Slightly volatile
Interest Income81.7 M94.5 M72.7 M
Slightly volatile
Reconciled Depreciation480.8 M759.1 M346.6 M
Slightly volatile
Extraordinary Items6.4 K6.8 K73 M
Slightly volatile

Jazz Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.8 B1.7 B714.4 M
Slightly volatile
Depreciation797 M759.1 M329 M
Slightly volatile
Capital Expenditures108.1 M55.3 M122.6 M
Pretty Stable
End Period Cash Flow2.9 B2.8 B978.6 M
Slightly volatile
Stock Based Compensation299.5 M285.3 M133.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.042.154.7002
Slightly volatile
Days Sales Outstanding42.2657.8756.8015
Slightly volatile
Stock Based Compensation To Revenue0.06920.07010.0622
Pretty Stable
Capex To Depreciation0.07960.08370.5561
Slightly volatile
EV To Sales5.743.215.6656
Slightly volatile
Inventory Turnover1.011.072.1538
Slightly volatile
Days Of Inventory On Hand182354262
Slightly volatile
Payables Turnover3.175.154.2269
Slightly volatile
Sales General And Administrative To Revenue0.390.370.3422
Pretty Stable
Research And Ddevelopement To Revenue0.420.250.2656
Pretty Stable
Capex To Revenue0.01290.01360.063
Pretty Stable
Cash Per Share45.7443.5619.1856
Slightly volatile
Days Payables Outstanding12973.33107
Slightly volatile
Intangibles To Total Assets0.470.480.6032
Very volatile
Current Ratio2.484.013.5443
Very volatile
Receivables Turnover7.996.536.5153
Slightly volatile
Graham Number11010572.6066
Slightly volatile
Capex Per Share1.370.72.0287
Pretty Stable
Revenue Per Share62.1859.2235.0865
Slightly volatile
Interest Debt Per Share97.8193.1548.7102
Slightly volatile
Debt To Assets0.510.590.3984
Slightly volatile
Operating Cycle224412318
Slightly volatile
Days Of Payables Outstanding12973.33107
Slightly volatile
Quick Ratio2.293.63.2471
Pretty Stable
Net Income Per E B T0.881.081.1477
Very volatile
Cash Ratio1.852.671.8583
Pretty Stable
Days Of Inventory Outstanding182354262
Slightly volatile
Days Of Sales Outstanding42.2657.8756.8015
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.991.110.8531
Pretty Stable
Fixed Asset Turnover19.5820.6129.9278
Slightly volatile
Debt Ratio0.510.590.3984
Slightly volatile
Price Sales Ratio2.042.154.7002
Slightly volatile
Asset Turnover0.510.390.3849
Pretty Stable
Gross Profit Margin0.710.80.8819
Slightly volatile

Jazz Fundamental Market Drivers

Forward Price Earnings8.5616
Cash And Short Term Investments3 B

Jazz Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Jazz Pharmaceuticals Financial Statements

Jazz Pharmaceuticals investors use historical fundamental indicators, such as Jazz Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jazz Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue133.5 M140.2 M
Total Revenue4.7 B4.9 B
Cost Of Revenue512.6 M538.2 M
Stock Based Compensation To Revenue 0.07  0.07 
Sales General And Administrative To Revenue 0.37  0.39 
Research And Ddevelopement To Revenue 0.25  0.42 
Capex To Revenue 0.01  0.01 
Revenue Per Share 59.22  62.18 
Ebit Per Revenue 0.16  0.17 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY